INmune Bio, Inc. (NASDAQ:INMB) Receives Average Rating of “Hold” from Analysts

Shares of INmune Bio, Inc. (NASDAQ:INMB) have been assigned a consensus rating of “Hold” from the six brokerages that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $8.00.

A number of equities research analysts have recently commented on the stock. Lucid Cap Mkts raised shares of INmune Bio from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 11th. Wall Street Zen raised INmune Bio from a “sell” rating to a “hold” rating in a report on Saturday, February 28th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of INMB. Intech Investment Management LLC purchased a new stake in shares of INmune Bio during the second quarter worth approximately $26,000. Cary Street Partners Financial LLC purchased a new position in INmune Bio in the 3rd quarter valued at $29,000. Independent Advisor Alliance acquired a new position in INmune Bio in the 3rd quarter valued at $30,000. Squarepoint Ops LLC acquired a new position in INmune Bio in the 3rd quarter valued at $30,000. Finally, Quadrature Capital Ltd purchased a new position in INmune Bio during the 4th quarter worth $26,000. 12.72% of the stock is currently owned by hedge funds and other institutional investors.

INmune Bio Trading Up 8.8%

Shares of INMB opened at $1.23 on Thursday. The firm has a market cap of $32.69 million, a PE ratio of -0.65 and a beta of 0.88. The company’s 50 day simple moving average is $1.39 and its 200-day simple moving average is $1.64. INmune Bio has a 12-month low of $1.09 and a 12-month high of $11.64.

INmune Bio (NASDAQ:INMB) last released its quarterly earnings results on Monday, March 30th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.09. As a group, equities research analysts forecast that INmune Bio will post -2.24 EPS for the current fiscal year.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.